Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
This is a study for people with a type of cancer called multiple myeloma who have already tried two other treatments that didn't work. There are three parts to the study: a screening phase, a phase where the person gets a new treatment for 28 days, and a follow-up phase. The new treatment includes three medications called isatuximab, elotuzumab, pomalidomide, and dexamethasone.
This is a study for people with a type of cancer called multiple myeloma who have already tried two other treatments that didn't work. There are three parts to the study: a screening phase, a phase where the person gets a new treatment for 28 days, and a follow-up phase. The new treatment includes three medications called isatuximab, elotuzumab, pomalidomide, and dexamethasone.
*Third Opinion AI Generated Synopsis
Trial Summary
This is a multicenter, open-label phase II study in subjects with relapsed and/or refractory multiple myeloma with at least two prior lines of therapy. The main study consists of three phases: a 28-day screening phase, treatment phase that consists of 28-day cycles of isatuximab with elotuzumab, pomalidomide, and dexamethasone and a follow-up phase.
This is a multicenter, open-label phase II study in subjects with relapsed and/or refractory multiple myeloma with at least two prior lines of therapy. The main study consists of three phases: a 28-day screening phase, treatment phase that consists of 28-day cycles of isatuximab with elotuzumab, pomalidomide, and dexamethasone and a follow-up phase.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
